Compare ATEN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | CDNA |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2014 | 2007 |
| Metric | ATEN | CDNA |
|---|---|---|
| Price | $24.62 | $50.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $26.33 | ★ $28.00 |
| AVG Volume (30 Days) | 987.8K | ★ 1.0M |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.28 | ★ 2.13 |
| Revenue | ★ $235,429,000.00 | $48,324,000.00 |
| Revenue This Year | $13.02 | $16.01 |
| Revenue Next Year | $10.82 | $11.31 |
| P/E Ratio | $88.54 | ★ $23.49 |
| Revenue Growth | 2.36 | ★ 18.93 |
| 52 Week Low | $16.52 | $13.39 |
| 52 Week High | $38.49 | $53.67 |
| Indicator | ATEN | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 34.66 | 60.71 |
| Support Level | $17.02 | $45.74 |
| Resistance Level | $28.39 | $53.67 |
| Average True Range (ATR) | 0.85 | 2.53 |
| MACD | 0.15 | -0.48 |
| Stochastic Oscillator | 15.65 | 51.17 |
A10 Networks Inc is a provider of secure application and network infrastructure solutions for enterprises and service providers across on-premises, hybrid cloud, and distributed environments. The company's offerings include application delivery and traffic management, distributed denial-of-service (DDoS) protection, application and API security, and centralized management. It serves customers across multiple industries, including telecommunications, technology, financial services, public sector, industrial, retail, gaming, and education. The majority of the company's revenue is derived from the sale of secure networking and cybersecurity solutions and related maintenance and support services.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.